A focused biopharma company
-
People worldwide
70k -
Countries we operate in
>75 -
Manufacturing sites
37
Innovation
-
R&D investment in 2023 (£)
6.2bn -
Global R&D centres in US, UK, Belgium and Italy
4 -
Major business development deals in 2023
6
Performance
-
Packs of medicines and doses of vaccines delivered
2.3bn -
Vaccine and medicine sales in 2023 (£)
30.3bn -
Sales growth in 2023
14% -
Sales of products launched in the last five years including lifecycle innovation (£)
10.0bn
Trust
-
In the Access to Medicine Index
1st -
In our industry for the S&P Global Corporate Sustainability Assessment
1st -
Reduction in Operational Carbon emissions
10% -
Global Health pipeline assets progressed to address priority WHO Diseases
12
Products and pipeline
-
Assets in the pipeline
71 -
Number of phase I programmes started in 2023
8 -
Number of assets in phase III/registration in 2023
18 -
Major new vaccines and medicines approved in 2023
4
-
Vaccine preventable diseases identified by WHO
23/32 -
Vaccine doses delivered each day
1.5m -
Children receiving a GSK vaccine each year
4 in 10 -
Candidate vaccines in our pipeline
19
-
To pioneer HIV treatments in 1980 and leaders in HIV innovation
1st -
To produce a new medicine for Lupus in 50+ years
1st -
Investigational medicines in our oncology pipeline
11
-
Patients reached with our general medicines over the next ten years
700m -
Medicines in our portfolio
150+ -
Helping millions of people with respiratory conditions to breathe more easily
50 years -
In 2023 sales grew to (£)
10.2bn